Iceland· IS-IS/1/18/090/01

Berinert

A c1-inhibitor, plasma derived product containing c1 esterase inhibitor (human), registered in Iceland by CSL Behring GmbH*. The same ATC class is registered in 11 of our 19 countries.

ATC B06AC01

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedBerinertATCB06AC01REGISTER NO.IS-IS/1/18/090/01PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

C1-inhibitor, plasma derived is registered in 11 of 19 countries.

Countries holding a registration under ATC B06AC01 (c1-inhibitor, plasma derived), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

C1-inhibitor, plasma derived · ATC B06AC01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
C1 ESTERASE INHIBITOR (HUMAN)
Manufacturer
CSL Behring GmbH*
Country
Iceland (IS)
ATC code
B06AC01
ATC class
C1-inhibitor, plasma derived
Defined daily dose
1.4 TSD, E
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

47 interactions on record for c1-inhibitor, plasma derived.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

C1-inhibitor, plasma derived · interactions on record

47 records

  • 5 severe
  • 42 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

C1-inhibitor, plasma derived in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All c1-inhibitor, plasma derived products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Berinert
  • Belgium · Berinert
  • Bulgaria · Беринерт
  • Cyprus · Berinert
  • Czechia · Berinert
  • Germany · Berinert
  • Denmark · Berinert
  • Estonia · Berinert Iv, Berinert Sc
  • Spain · Berinert
  • Finland · Berinert
  • France · Berinert
  • United Kingdom (Northern Ireland) · Berinert
  • Greece · Berinert
  • Croatia · Berinert
  • Hungary · Berinert
  • Ireland · Berinert
  • Italy · Berinert
  • Liechtenstein · Cinryze
  • Lithuania · Human C1-Esterase Inhibitor Csl Behring
  • Luxembourg · Berinert
  • Malta · Berinert
  • Netherlands · Berinert
  • Norway · Berinert, Cinryze
  • Poland · Berinert
  • Portugal · Berinert
  • Romania · Berinert
  • Sweden · Berinert
  • Slovenia · Berinert
  • Slovakia · Berinert

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4c150fc0-8daf-4c70-9f5e-2b1d3bf3d0aa
GET /v1/drugs/4c150fc0-8daf-4c70-9f5e-2b1d3bf3d0aa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyfs-/innrennslisstofn og leysir, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "B06AC01",
  "marketed": true,
  "strength": "500 a.e.",
  "ma_number": "IS/1/18/090/01",
  "substance": "C1 ESTERASE INHIBITOR (HUMAN)",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í ónæmisfræði.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "43334"
}

See everything about c1-inhibitor, plasma derived.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.